Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jenny Jing Li is originally from China. She earned her undergraduate degree from Duke University where she majored in neuroscience and biology. She received her M.D. degree from Duke University School of Medicine and completed her Internal Medicine residency at University of Texas Southwestern Medical Center. She is currently undergoing her hematology/oncology fellowship training at Mayo Clinic in Rochester, MN

Mandarin Lung Cancer Video Library - The Leading Treatment Options for Advanced NSCLC and High PDL-1
dbrock
普通话肺癌视频库-晚期NSCLC和高PDL-1的领先治疗方案
Author
Jenny J. Li, MD, GRACE Guest Faculty
Image
Dr. Jenni Li joins GRACE as guest faculty to provide updated information to our Mandarin Lung Cancer Video Library, for our mandarin speaking community.

In this video, Dr. Li shares information on the leading treatment options for patients with advanced NSCLC and high tumor PD-L1 expression.

To join the conversation, visit https://cancergrace.org/forum.

李仁妮博士加入GRACE,担任客座教授,为普通话社区提供最新信息给我们的普通话肺癌视频库。 在此视频中,李医生分享了晚期NSCLC和高肿瘤PD-L1表达患者的主要治疗选择的信息。

Video Language

Next Previous link

Previous PostNext Post

Online Community

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)

There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...

Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.

The...

Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...

Hi Stan!  So good to hear from you.  I'm sorry for the late response.  I too have been out of town with family and missed your post, probably because I was...

It is so good to hear from you!  And I am so happy to hear that your holidays have been good and that you are doing well.  It sounds like your...

Recent Comments

JOIN THE CONVERSATION
Biomarkers
By JanineT GRACE … on
Radiation Therapy
By JanineT GRACE … on
Oligometastatic vs Oligoprogression
By JanineT GRACE … on
Hi Stan!! and happiest of holidays!
By dbrock on